Brief: Galectin Therapeutics Inc Says Joel Lewis Assumes CEO Role
09/11/2020 13:16
Nov 9 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS INC - BOARD MEMBER JOEL LEWIS
ASSUMES CEO
ROLE
* GALECTIN THERAPEUTICS INC - BOARD ADDS TWO NEW
PROFESSIONALS
* GALECTIN THERAPEUTICS INC - INNOVATIVE PHASE 2B/3 NASH-RX
TRIAL
IN NASH CIRRHOSIS INITIATED
* GALECTIN THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.10
Source: (https://bit.ly/3lejW0y)
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study